Serpin B-7 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Serpin B-7 (SERPINB7/Megsin, UniProt O75635) expressed in HEK293 cells. Suited for protease inhibition assays, inhibitor screening, and antibody validation paired with RP-SerpinB7.
Expression system
HEK293
Cat. #
REC-SerpinB7

In stock

SKU
REC-SerpinB7
$498.00

Target Overview

Serpin B-7 (gene: SERPINB7; also known as Megsin and TP55) is a 380-amino-acid intracellular member of the clade B serine protease inhibitor (serpin) superfamily, catalogued under UniProt accession O75635. Unlike the secreted serpins, Serpin B-7 localises to the cytoplasm, consistent with a role in regulating intracellular Lys-specific proteolytic activity. It has additionally been studied for a proposed function in megakaryocyte maturation. This recombinant protein is produced in HEK293 mammalian cells, providing a eukaryotic post-translational processing environment that preserves native folding characteristics relevant to inhibitory conformation studies. The full-length sequence span of 380 residues is the basis for the expressed construct. Researchers use this recombinant in several experimental contexts. In protease inhibitor studies, it serves as the inhibitory partner in substrate-competition or residual-activity assays against candidate Lys-specific proteases. In inhibitor screening workflows, it provides a defined, recombinant benchmark for IC50 determination. The protein is also used as a positive-control loading standard for Western blot and immunohistochemistry validation — researchers pairing this recombinant with the matched Triple Point Biologics antibody (SKU: RP-SerpinB7) can confirm band identity and establish signal linearity. Its HEK293 origin makes it a suitable standard in cell-lysate comparisons where endogenous glycosylation patterns are relevant. Species reactivity is validated for human; cross-reactivity with monkey orthologues is predicted based on sequence homology.

Background

Serpin B-7 (SERPINB7) belongs to the large and structurally conserved serpin superfamily, a group of proteins defined by a characteristic stressed-to-relaxed conformational transition that underlies their protease-trapping mechanism. Clade B serpins, including Serpin B-7, are notable for lacking an N-terminal signal peptide and for their cytoplasmic or nuclear localisation — distinguishing them from the archetypal plasma serpins such as antithrombin and alpha-1-antitrypsin. The reactive centre loop (RCL) of Serpin B-7 contains features consistent with specificity toward Lys-cleaving serine proteases, though the precise endogenous protease target(s) remain an active area of research. SERPINB7 was originally identified as Megsin in studies of megakaryocyte biology, where expression data suggested a regulatory role in megakaryocyte differentiation — a function consistent with the cytoplasmic distribution of the protein. The gene subsequently attracted broader research attention following genetic studies linking loss-of-function variants to Nagashima-type palmoplantar keratoderma (NPPK), a hereditary skin disorder characterised by diffuse palmoplantar hyperkeratosis. Functional characterisation studies have examined how specific in-frame indels and founder variants in SERPINB7 disrupt normal protein conformation or expression, using recombinant protein and cell-based models to interrogate pathogenic mechanisms (Liu J et al., J Dermatol, 2026; PMID 41656929). Separately, ARMS-qPCR strategies for rapid genetic diagnosis of NPPK have been developed and validated against reference sequence data derived from published SERPINB7 variant catalogues (Zhang J et al., J Dermatol, 2026; PMID 41891421). Small-molecule readthrough compounds targeting nonsense variants in SERPINB7 have also been characterised in cell-based assays (Peh JT et al., J Dermatol Sci, 2026; PMID 42034525), a context in which recombinant Serpin B-7 can serve as a reference standard for restored protein detection. Beyond dermatological research, SERPINB7 expression has been detected in oncology-focused multi-omic profiling studies. Integrated genomic and proteomic analyses of cervical cancer identified SERPINB7 among proteins associated with chemoradiation resistance signatures (Sambath J et al., Mol Oncol, 2026; PMID 41586744). Additionally, a role for SERPINB7 in promoting c-Myc-mediated glycolysis through interaction with Annexin A2 (ANXA2) has been reported in non-small cell lung cancer models (Zhao F et al., Mol Cancer, 2026; PMID 42310746), positioning the protein as a research target in metabolic reprogramming studies. These findings collectively make recombinant Serpin B-7 a useful tool for researchers designing pull-down, co-immunoprecipitation, and antibody validation experiments across multiple disease-relevant biological contexts.

Applications

  • Protease inhibition activity assay against candidate Lys-specific serine proteases
  • Inhibitor IC50 determination in competitive substrate cleavage assays
  • Western blot positive-control standard for anti-SERPINB7 antibody validation (pair with SKU RP-SerpinB7)
  • IHC antibody titration and signal linearity standard
  • Pull-down or co-immunoprecipitation assay to study SERPINB7–ANXA2 protein–protein interaction
  • Cell-free reference standard for quantifying SERPINB7 protein restoration in nonsense-readthrough compound studies
  • Multi-omic proteomic reference material for mass spectrometry-based protein identification and quantification
  • Recombinant antigen for epitope mapping of anti-Serpin B-7 antibodies

References

  1. Zhao F et al. SerpinB7 promotes c-Myc-mediated glycolysis by interacting with ANXA2 to facilitate the progression of non-small cell lung cancer. Mol Cancer. 2026. doi:10.1186/s12943-026-02684-9. PMID: 42310746.
  2. Peh JT et al. Identification of novel small molecule compounds with readthrough activity in Nagashima-type palmoplantar keratosis. J Dermatol Sci. 2026. doi:10.1016/j.jdermsci.2026.02.001. PMID: 42034525.
  3. Zhang J et al. Development of an ARMS-qPCR Strategy for the Rapid Genetic Diagnosis of Nagashima-Type Palmoplantar Keratoderma. J Dermatol. 2026. doi:10.1111/1346-8138.70239. PMID: 41891421.
  4. Liu J et al. Functional Characterization of a Novel In-Frame Indel and a Founder Variant in SERPINB7 Associated With Palmoplantar Keratoderma. J Dermatol. 2026. doi:10.1111/1346-8138.70148. PMID: 41656929.
  5. Sambath J et al. Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer. Mol Oncol. 2026. doi:10.1002/1878-0261.70108. PMID: 41586744.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma

Frequently Asked Questions

What molecular weight should recombinant Serpin B-7 run at on SDS-PAGE or Western blot?

The full-length 380-amino-acid Serpin B-7 construct (UniProt O75635) has a calculated molecular weight of approximately 42 kDa. On reducing SDS-PAGE, expect a band in the 42–45 kDa range; minor upward shift relative to the predicted MW is common with HEK293-expressed proteins due to glycosylation or other post-translational modifications. Under non-reducing conditions, the apparent MW may shift slightly. Purity is confirmed >95% by SDS-PAGE prior to release. If your observed band deviates significantly from this range, contact us with your gel conditions.

Is recombinant Serpin B-7 full-length or a truncated fragment, and does it retain inhibitory activity?

This construct covers the complete 380-residue sequence of human Serpin B-7 (SERPINB7), expressed in HEK293 mammalian cells to preserve native eukaryotic folding. The reactive center loop (RCL), which is essential for serine protease inhibitory conformation, is intact. Production in HEK293 rather than E. coli is specifically chosen to support correct disulfide environment and folding relevant to inhibitory activity assays. This is the full-length isoform; no truncation or signal peptide clipping is expected for this intracellular clade B serpin.

What protease does Serpin B-7 inhibit, and what substrate or enzyme should I use in an activity assay?

Serpin B-7 (Megsin) has been characterized as an inhibitor of Lys-specific serine proteases. For residual-activity assays, plasmin is a commonly used model enzyme partner given its Lys-preferring cleavage specificity. A fluorogenic substrate such as H-D-Val-Leu-Lys-AMC or the chromogenic H-D-Ala-Lys-pNA can be used to monitor residual protease activity after incubation with Serpin B-7. Pre-incubate the serpin with the target protease (molar ratios of 2:1 to 10:1 serpin:protease) in assay buffer before adding substrate, then measure inhibition relative to a no-serpin control.

What buffer conditions are recommended for Serpin B-7 inhibitory activity assays, and is the storage buffer compatible?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — is compatible with most serpin activity assays at typical working dilutions (1:5 or greater). For sensitive fluorogenic assays, dilute into your assay buffer (e.g., 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.01% Tween-20) to bring glycerol below 2%, which can otherwise reduce enzyme velocity. Avoid EDTA if your target protease is calcium-dependent. pH 7.4–7.5 is appropriate for preserving the inhibitory conformation of clade B serpins.

What starting concentration of recombinant Serpin B-7 should I use for IC50 or stoichiometry of inhibition experiments?

For stoichiometry-of-inhibition (SI) experiments, titrate Serpin B-7 at molar ratios of 1:1 to 20:1 against your target protease, keeping protease concentration fixed (typically 1–10 nM for sensitive fluorogenic readouts). For IC50 determinations in competition assays, a working range of 10–1000 nM Serpin B-7 is a practical starting point. Because clade B serpins can behave as suicide inhibitors with SI values >1, include a substrate-competition control to distinguish true inhibition from stoichiometric trapping. Protein concentration is provided on the vial Certificate of Analysis.

Can I use recombinant Serpin B-7 as a positive control for Western blot with the matched TPB anti-Serpin B-7 antibody (RP-SerpinB7)?

Yes — this is a validated use case. The matched rabbit polyclonal antibody RP-SerpinB7 (/anti-serpin-b7-rabbit-polyclonal-antibody) was raised against Serpin B-7 and is confirmed compatible with this recombinant protein on Western blot. Load 10–50 ng of recombinant Serpin B-7 per lane alongside your cell lysate samples. Expect a clean band at approximately 42–45 kDa. This pairing is particularly useful for confirming antibody performance and establishing a reliable size reference when probing endogenous Serpin B-7 in megakaryocyte or keratinocyte lysates.

How much recombinant Serpin B-7 should I load for a Western blot positive control lane?

A loading range of 10–50 ng per lane is sufficient for a strong positive control signal when using the matched RP-SerpinB7 rabbit polyclonal antibody. Start with 25 ng to establish baseline signal, then titrate down to 10 ng if background is an issue or up to 50 ng if signal is weak with your secondary antibody system. Run on a 10–12% SDS-PAGE gel for optimal resolution in the 40–50 kDa range. Ensure the lane is not overloaded, as serpin proteins at high concentration can appear as a doublet due to native vs. cleaved (relaxed) conformer migration differences.

How should I store and handle recombinant Serpin B-7 to maintain activity, and what is the shelf life?

Store at -20°C in single-use aliquots upon receipt. The supplied buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) stabilizes the protein during freeze-thaw, but repeated freeze-thaw cycles should be avoided as they accelerate conformational drift in serpins and can populate the latent (inactive) conformation. Shelf life is 12 months from date of receipt when stored correctly. After thawing, keep on ice and use within 4–8 hours. Do not dilute to below approximately 0.1 mg/mL in plain buffer without adding a carrier protein (e.g., 0.1% BSA) to prevent adsorption losses.

Validation imagery coming soon

Western blot validation figures for REC-SerpinB7 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →